BGC-0228 is under clinical development by BrightGene Bio-Medical Technology and currently in Phase I for Epithelial Ovarian Cancer. According to GlobalData, Phase I drugs for Epithelial Ovarian Cancer have an 85% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how BGC-0228’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BGC-0228 is under development for the treatment of solid tumors including breast cancer, metastatic pancreatic cancer, epithelial ovarian cancer, gastric cancer, esophageal cancer, non-small cell lung cancer, small-cell lung cancer. It is administered through parenteral route. The drug candidate comprises polymer conjugated with cytotoxic drug and is developed based on targeted polymer coupling platform.
BrightGene Bio-Medical Technology overview
BrightGene Bio-Medical Technology (BrightGene) is a biopharmaceutical company that manufacturing, research and develop of generic drugs. The company’s pipeline products include posaconazole, oseltamivir phosphate, orivancin, fidaxomycin, agatroban, fondaparinux, acarbose, iron supplements, trabectidine, pemetrexed disodium intermediate, eribulin mesylate, midotolin, everolimus and pimecrolimus, among others. Its veterinary drugs includes seramectin, telavancin hydrochloride, emodes, doramectin and dalbavancin. The company develops products in the therapeutic areas of cardiology, oncology, antibacterial, antifungal and veterinary. BrightGene is headquartered in Suzhou, Jiangsu, China.
For a complete picture of BGC-0228’s drug-specific PTSR and LoA scores, buy the report here.